SCHEMBL560769

SCHEMBL560769

COc1cccc(CNC2=NCCN2)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1A P35348 1/20 0.51
ADRA1B P35368 1/20 0.51
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.50
MAPK1 P28482 2/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
WDR5 P61964 7/20 0.48
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NLRP3 Q96P20 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
NPSR1 Q6W5P4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670018 0.88 LMNA (0.54) GAAWDR5LMNASMN1; SMN2NLRP3
SCHEMBL561212 0.86 WDR5 (0.48) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL4823054 0.78 KCNH2 (0.50) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL953395 0.77 TAAR1 (0.55) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL4788240 0.77 ADRA2A (0.44) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL9440518 0.76 NISCH (0.50) ADRA2AADRA2BADRA2CMAPK1
SCHEMBL561022 0.75 HTR1D (0.55) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL560664 0.75 LMNA (0.56) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL561423 0.74 LMNA (0.56) GAAWDR5LMNASMN1; SMN2NLRP3
SCHEMBL8133611 0.74 LMNA (0.54) ADRA2AADRA2BADRA2CGAAWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303264-B1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES ALLERGAN INC (US) 2018-04-04 EP claimed
US-20150224080-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. 2015-08-13 US claimed
US-9034910-B2 Methods of treating alpha adrenergic mediated conditions ALLERGAN, INC. (US) 2015-05-19 US claimed
US-20120165380-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2012-06-28 US claimed
US-20120035235-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2012-02-09 US claimed
US-8071636-B2 Methods of treating alpha adrenergic mediated conditions ALLERGAN, INC. (US) 2011-12-06 US claimed
CN-102099032-A Methods of treating alpha adrenergic mediated conditions ALLERGAN INC 2011-06-15 CN claimed
EP-2303264-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS Allergan, Inc. (US) 2011-04-06 EP claimed
WO-2009152052-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-17 WO claimed
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 US claimed
US-20230062049-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. 2023-03-02 US disclosed
US-20230062049-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. 2023-03-02 US disclosed
US-20200330428-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN INC (US) 2020-10-22 US disclosed
US-20200330428-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN INC (US) 2020-10-22 US disclosed
US-20180344692-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN INC (US) 2018-12-06 US disclosed
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 US disclosed
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 US disclosed
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 US disclosed
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 US disclosed
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2C, ADRA2A ADRA2A 3/4885ADRA2B 7/4885ADRA2C 2/4885
US-20230062049-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C ADRA2A 2/4885ADRA2B 7/4885ADRA2C 3/4885
US-20150224080-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C ADRA2A 2/4885ADRA2B 7/4885ADRA2C 3/4885
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2C, ADRA2A ADRA2A 3/4885ADRA2B 7/4885ADRA2C 2/4885
US-20120035235-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2C, ADRA2A ADRA2A 3/4885ADRA2B 7/4885ADRA2C 2/4885
US-20200330428-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C ADRA2A 2/4885ADRA2B 7/4885ADRA2C 3/4885
US-20180344692-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C ADRA2A 2/4885ADRA2B 7/4885ADRA2C 3/4885
US-20120165380-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C ADRA2A 2/4885ADRA2B 7/4885ADRA2C 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.